#Chr	Start	End	Ref	Alt	Ref.Gene	Func.refGene	ExonicFunc.refGene	Gene.ensGene	avsnp147	AAChange.ensGene	AAChange.refGene	clinvar: Clinvar 	 CancerVar: CancerVar and Evidence 	Freq_ExAC_ALL	Freq_esp6500siv2_all	Freq_1000g2015aug_all	Freq_gnomAD_genome_ALL	CADD_raw	CADD_phred	SIFT_score	GERP++_RS	phastCons20way_mammalian	dbscSNV_ADA_SCORE	dbscSNV_RF_SCORE	Interpro_domain	AAChange.knownGene	MetaSVM_score	Freq_gnomAD_genome_POPs	OMIM	Phenotype_MIM	OrphaNumber	Orpha	Pathway	Therap_list	Diag_list	Prog_list	Polyphen2_HDIV_score	FATHMM_score	MetaLR_score	MutationAssessor_score	cosmic91	icgc28	Otherinfo
9	133748283	133748283	C	T	ABL1	exonic	nonsynonymous SNV	ENSG00000097007	rs121913459	ENSG00000097007:ENST00000318560:exon6:c.C944T:p.T315I,ENSG00000097007:ENST00000372348:exon6:c.C1001T:p.T334I	ABL1:NM_005157:exon6:c.C944T:p.T315I,ABL1:NM_007313:exon6:c.C1001T:p.T334I	clinvar: Pathogenic/Likely_pathogenic 	 CancerVar: 8#Tier_II_potential EVS=[1, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1] 	.	.	.	.	6.838	33	0.002	6.04	0.992	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	ABL1:uc004bzv.3:exon6:c.C1001T:p.T334I,ABL1:uc004bzw.3:exon6:c.C944T:p.T315I	-0.417	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	189980	.	.	.	~ko04012 ErbB signaling pathway~ko04014 Ras signaling pathway~ko04110 Cell cycle~ko04360 Axon guidance~ko04722 Neurotrophin signaling pathway~ko05130 Pathogenic Escherichia coli infection~ko05131 Shigellosis~ko05200 Pathways in cancer~ko05206 MicroRNAs in cancer~ko05220 Chronic myeloid leukemia~ko05416 Viral myocarditis~	299,303,309,,304,300,302,308,301,307,305,306,155	.	.	0.999	-0.02	0.314	0.565	ID=COSV59323790;OCCURENCE=66(haematopoietic_and_lymphoid_tissue),2(skin)	.	
14	105246551	105246551	C	T	AKT1	exonic	nonsynonymous SNV	ENSG00000142208	rs121434592	ENSG00000142208:ENST00000554581:exon2:c.G49A:p.E17K,ENSG00000142208:ENST00000402615:exon3:c.G49A:p.E17K,ENSG00000142208:ENST00000407796:exon3:c.G49A:p.E17K,ENSG00000142208:ENST00000554848:exon3:c.G49A:p.E17K,ENSG00000142208:ENST00000555528:exon3:c.G49A:p.E17K,ENSG00000142208:ENST00000349310:exon4:c.G49A:p.E17K,ENSG00000142208:ENST00000555926:exon4:c.G49A:p.E17K	AKT1:NM_001014431:exon3:c.G49A:p.E17K,AKT1:NM_005163:exon3:c.G49A:p.E17K,AKT1:NM_001014432:exon4:c.G49A:p.E17K	clinvar: Pathogenic/Likely_pathogenic 	 CancerVar: 10#Tier_II_potential EVS=[2, 0, 0, 1, 0, 0, 1, 1, 2, 1, 1, 1] 	8.427e-06	.	.	.	6.534	31	0.01	4.61	0.955	.	.	Pleckstrin homology domain;Pleckstrin homology-like domain	AKT1:uc001ypl.3:exon2:c.G49A:p.E17K,AKT1:uc001ypk.3:exon3:c.G49A:p.E17K,AKT1:uc001ypn.3:exon3:c.G49A:p.E17K,AKT1:uc010axa.3:exon3:c.G49A:p.E17K,AKT1:uc001ypm.3:exon4:c.G49A:p.E17K	-0.641	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164730	114480;114500;167000;176920;181500;615109;	201;744;227535;	201|Cowden disease<br>Multiple hamartoma syndrome|1-9 / 1 000 000|Autosomal dominant|All ages|158350 612359 615106 615107 615108 615109 616858 ~744|Partial gigantism-nevi-hemihypertrophy-macrocephaly syndrome|<1 / 1 000 000|Not applicable|Infancy|176920 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko01524 Platinum drug resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04022 cGMP-PKG signaling pathway~ko04024 cAMP signaling pathway~ko04062 Chemokine signaling pathway~ko04066 HIF-1 signaling pathway~ko04068 FoxO signaling pathway~ko04071 Sphingolipid signaling pathway~ko04072 Phospholipase D signaling pathway~ko04140 Autophagy - animal~ko04150 mTOR signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04152 AMPK signaling pathway~ko04210 Apoptosis~ko04211 Longevity regulating pathway~ko04212 Longevity regulating pathway - worm~ko04213 Longevity regulating pathway - multiple species~ko04218 Cellular senescence~ko04261 Adrenergic signaling in cardiomyocytes~ko04370 VEGF signaling pathway~ko04371 Apelin signaling pathway~ko04380 Osteoclast differentiation~ko04510 Focal adhesion~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04611 Platelet activation~ko04620 Toll-like receptor signaling pathway~ko04625 C-type lectin receptor signaling pathway~ko04630 JAK-STAT signaling pathway~ko04660 T cell receptor signaling pathway~ko04662 B cell receptor signaling pathway~ko04664 Fc epsilon RI signaling pathway~ko04666 Fc gamma R-mediated phagocytosis~ko04668 TNF signaling pathway~ko04722 Neurotrophin signaling pathway~ko04725 Cholinergic synapse~ko04728 Dopaminergic synapse~ko04910 Insulin signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04915 Estrogen signaling pathway~ko04917 Prolactin signaling pathway~ko04919 Thyroid hormone signaling pathway~ko04920 Adipocytokine signaling pathway~ko04922 Glucagon signaling pathway~ko04923 Regulation of lipolysis in adipocytes~ko04926 Relaxin signaling pathway~ko04929 GnRH secretion~ko04931 Insulin resistance~ko04932 Non-alcoholic fatty liver disease (NAFLD)~ko04933 AGE-RAGE signaling pathway in diabetic complications~ko04973 Carbohydrate digestion and absorption~ko05135 Yersinia infection~ko05142 Chagas disease (American trypanosomiasis)~ko05145 Toxoplasmosis~ko05152 Tuberculosis~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05162 Measles~ko05163 Human cytomegalovirus infection~ko05164 Influenza A~ko05165 Human papillomavirus infection~ko05166 Human T-cell leukemia virus 1 infection~ko05167 Kaposi sarcoma-associated herpesvirus infection~ko05168 Herpes simplex virus 1 infection~ko05169 Epstein-Barr virus infection~ko05170 Human immunodeficiency virus 1 infection~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05222 Small cell lung cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~ko05418 Fluid shear stress and atherosclerosis~	,365,356,392,395,367,366,361,368,371,378,382,396,393,359,383,390,347,349,345,376,384,369,350,360,357,348,373,374,394,353,380,363,362,377,358,364,354,344,391,352,372,379,346,381,370,351,375,355	.	.	1.0	1.17	0.222	2.175	ID=COSV62571334;OCCURENCE=5(salivary_gland),262(breast),2(peritoneum),5(cervix),69(meninges),46(large_intestine),2(central_nervous_system),3(biliary_tract),5(ovary),15(bone),6(NS),3(stomach),7(haematopoietic_and_lymphoid_tissue),1(kidney),18(soft_tissue),22(urinary_tract),5(pancreas),58(skin),16(prostate),24(lung),27(thyroid),11(upper_aerodigestive_tract),1(thymus),31(endometrium)	MU10466	
7	140453136	140453136	A	T	BRAF	exonic	nonsynonymous SNV	ENSG00000157764	rs113488022	ENSG00000157764:ENST00000479537:exon2:c.T83A:p.V28E,ENSG00000157764:ENST00000288602:exon15:c.T1799A:p.V600E	BRAF:NM_004333:exon15:c.T1799A:p.V600E	clinvar: Pathogenic 	 CancerVar: 11#Tier_I_strong EVS=[1, 1, 1, 1, 0, 0, 1, 1, 2, 1, 1, 1] 	1.65e-05	.	.	.	6.642	32	0.001	5.65	1.000	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain	BRAF:uc003vwc.4:exon15:c.T1799A:p.V600E	-0.768	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164757	115150;211980;613706;613707;	500;648;1340;	500|Cardiomyopathic lentiginosis<br>Familial multiple lentigines syndrome<br>LEOPARD syndrome|Unknown|Autosomal dominant|Childhood|151100 611554 613707 ~648|-|Unknown|Autosomal dominant|Neonatal|163950 605275 609942 610733 611553 613224 613706 615355 616559 616564 ~1340|CFC syndrome|Unknown|Autosomal dominant|Antenatal<br>Neonatal|115150 615278 615279 615280 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04015 Rap1 signaling pathway~ko04024 cAMP signaling pathway~ko04062 Chemokine signaling pathway~ko04068 FoxO signaling pathway~ko04150 mTOR signaling pathway~ko04214 Apoptosis - fly~ko04270 Vascular smooth muscle contraction~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04650 Natural killer cell mediated cytotoxicity~ko04720 Long-term potentiation~ko04722 Neurotrophin signaling pathway~ko04726 Serotonergic synapse~ko04730 Long-term depression~ko04810 Regulation of actin cytoskeleton~ko04910 Insulin signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05034 Alcoholism~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05216 Thyroid cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~	,1338,1327,1569,1348,1631,1318,1486,1401,1413,1589,1544,1499,1601,1357,1522,1492,1229,1491,1487,1282,1207,1632,1369,1215,1576,1341,1447,1199,1426,1633,1216,1306,1301,1195,1329,1455,1350,1193,1373,1420,1496,1504,1561,1399,1291,1339,1410,1473,1322,1433,1344,1311,1184,1558,1541,1421,1619,1444,1438,1577,1531,1300,1204,1366,1362,1520,1620,1511,1424,1630,1226,1456,1246,1528,1186,1174,1345,1483,1389,1290,1224,1532,1223,1590,1189,1459,1167,1390,1166,1534,1173,1310,1470,1196,1622,1457,1359,1503,996,1360,1182,1562,1288,1179,1474,1445,1393,1302,1468,1303,1381,1408,1378,1377,1200,1461,1616,1354,1573,1305,1460,1295,1197,1208,1284,1555,1325,1346,1602,1172,1304,1570,1552,1315,1180,1586,1542,1446,1557,1553,1004,1449,1323,1414,1624,1331,1458,1527,1467,1423,1397,1564,1465,1600,1495,1530,1343,1642,1190,1439,1332,1337,1614,1312,1549,1490,1191,1612,1516,1194,1356,1372,1220,1407,1485,1488,1497,1466,1187,1559,1480,1643,1588,1448,1340,1412,1353,1171,1610,1368,1508,1436,1395,1398,1363,1371,1000,1572,1352,1203,1386,1227,1545,1370,1506,1517,1205,1547,1617,1402,1604,1609,1228,1416,1285,1509,1328,1297,1464,1336,1404,1326,1451,1334,1463,1529,1324,1641,1453,1316,1510,1598,1330,1425,1594,1287,1355,1202,1554,1213,1493,1365,1469,1580,1518,1211,1479,1524,1475,1623,1507,1427,1462,1502,1477,1293,1484,1165,1574,1514,1299,1537,1627,1608,1442,1351,1188,1505,1375,1177,1550,1212,1551,1575,1170,1593,1611,1613,1319,1006,1219,1289,1626,1428,1481,1452,1181,1415,1546,1361,1543,1007,1519,1001,1579,1581,1419,1441,1003,1584,1400,1298,1566,1512,1606,1405,1342,1591,1418,1536,1283,1443,1476,1294,1440,1437,1629,1176,1539,1513,1333,1296,1538,1526,1201,1175,1349,1388,1391,1607,1500,1628,1409,1192,1521,1406,1563,1387,1489,1210,1218,1525,1206,1585,1501,1472,1313,1374,1198,1560,1335,1002,1482,1597,1358,1587,1178,1168,1317,1403,1634,1515,1615,1596,1432,1314,1583,1005,1556,1394,1548,1571,1618,1595,1321,1209,1498,1450,1183,1605,1225,1567,1422,1222,1392,1286,1471,1565,1364,1454,1320,1599,1621,1309,1592,1568,1169,1347,1431,1494,1217,1396,1411,1221,1214,1535,1308,1380,1379,1533,1578,1523,1417,1376,1307,1478,1434,1185	,1625,1429,1640,1430	1382,,1635,1230,1367,1383,1540,1231,1582,1384,1385,1638,1232,1637,1639,1636	0.971	-1.53	0.236	1.32	ID=COSV56056643;OCCURENCE=9(salivary_gland),20(breast),1(female_genital_tract_(site_indeterminate)),19(liver),2(oesophagus),4(genital_tract),6(adrenal_gland),3(meninges),5352(large_intestine),421(central_nervous_system),28(biliary_tract),1(pleura),261(ovary),37(bone),1038(NS),4(stomach),856(haematopoietic_and_lymphoid_tissue),9(urinary_tract),31(kidney),58(soft_tissue),23(pancreas),3(autonomic_ganglia),91(pituitary),5930(skin),3(prostate),158(lung),14413(thyroid),13(upper_aerodigestive_tract),12(testis),95(eye),10(small_intestine),3(endometrium)	MU62030	
7	55249071	55249071	C	T	EGFR	exonic	nonsynonymous SNV	ENSG00000146648	rs121434569	ENSG00000146648:ENST00000455089:exon19:c.C2234T:p.T745M,ENSG00000146648:ENST00000275493:exon20:c.C2369T:p.T790M,ENSG00000146648:ENST00000454757:exon20:c.C2210T:p.T737M	EGFR:NM_005228:exon20:c.C2369T:p.T790M	clinvar: drug_response 	 CancerVar: 9#Tier_II_potential EVS=[1, 0, 1, 1, 0, 0, 1, 0, 2, 1, 1, 1] 	4.122e-05	.	.	9.688e-05	7.364	34	0.003	5.92	0.986	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	EGFR:uc022ado.1:exon1:c.C74T:p.T25M,EGFR:uc010kzg.2:exon19:c.C2234T:p.T745M,EGFR:uc022adn.1:exon19:c.C2234T:p.T745M,EGFR:uc003tqk.3:exon20:c.C2369T:p.T790M,EGFR:uc011kco.2:exon20:c.C2210T:p.T737M,EGFR:uc022adm.1:exon20:c.C2369T:p.T790M	-0.467	AFR:0.0002,AMR:0,EAS:0,FIN:0,NFE:6.668e-05,OTH:0,ASJ:0	131550	211980;616069;	294023;	294023|-|<1 / 1 000 000|Autosomal recessive|Infancy<br>Neonatal|614328 616069 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04020 Calcium signaling pathway~ko04066 HIF-1 signaling pathway~ko04068 FoxO signaling pathway~ko04072 Phospholipase D signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04214 Apoptosis - fly~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04520 Adherens junction~ko04540 Gap junction~ko04630 JAK-STAT signaling pathway~ko04810 Regulation of actin cytoskeleton~ko04912 GnRH signaling pathway~ko04915 Estrogen signaling pathway~ko04921 Oxytocin signaling pathway~ko04926 Relaxin signaling pathway~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05120 Epithelial cell signaling in Helicobacter pylori~~ko05160 Hepatitis C~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~	3548,3551,,3516,3234,3513,3486,3215,3253,3511,3538,2506,3243,3532,3259,3233,3228,3481,3480,3217,3244,3492,3267,3550,3230,3246,3227,3529,3240,3509,3247,3212,3518,3528,3552,3248,3549,3512,3211,3495,3238,3502,3498,3524,3527,3500,3241,3533,3547,3231,3506,3517,3484,3540,3537,3520,3264,3226,3508,3222,3525,3545,3539,3493,3535,3496,3269,2510,3488,3213,3261,3494,3268,3505,3489,3490,3262,3218,3544,3526,3543,3554,3531,3229,3219,3224,3232,2509,3252,3258,3499,3370,3482,3235,3483,3254,3237,3256,3251,3522,3515,3223,3555,3260,3507,3214,3263,3504,3510,2523,3497,3536,3245,3236,3242,3503,3239,3257,3220,3523,3534,3225,3546,3487,3530,3221,3553,3521,2507,3501,3491,3216,2508,3519,3265,3514,3255,3485,2712,3266	.	,3542,3249,3250,3541	1.0	0.24	0.317	1.17	ID=COSV51765492;OCCURENCE=3(breast),1(large_intestine),1(central_nervous_system),10(biliary_tract),1(soft_tissue),376(lung),2(upper_aerodigestive_tract)	MU131799503	
7	55259524	55259524	T	A	EGFR	exonic	nonsynonymous SNV	ENSG00000146648	rs121913444	ENSG00000146648:ENST00000455089:exon20:c.T2447A:p.L816Q,ENSG00000146648:ENST00000275493:exon21:c.T2582A:p.L861Q,ENSG00000146648:ENST00000454757:exon21:c.T2423A:p.L808Q	EGFR:NM_005228:exon21:c.T2582A:p.L861Q	clinvar: Pathogenic/Likely_pathogenic,_drug_response 	 CancerVar: 10#Tier_II_potential EVS=[1, 0, 1, 1, 0, 0, 1, 1, 2, 1, 1, 1] 	.	.	.	.	6.420	29.7	0.009	5.82	0.980	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	EGFR:uc022ado.1:exon2:c.T287A:p.L96Q,EGFR:uc010kzg.2:exon20:c.T2447A:p.L816Q,EGFR:uc022adn.1:exon20:c.T2447A:p.L816Q,EGFR:uc003tqk.3:exon21:c.T2582A:p.L861Q,EGFR:uc011kco.2:exon21:c.T2423A:p.L808Q,EGFR:uc022adm.1:exon21:c.T2582A:p.L861Q	0.243	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	131550	211980;616069;	294023;	294023|-|<1 / 1 000 000|Autosomal recessive|Infancy<br>Neonatal|614328 616069 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04020 Calcium signaling pathway~ko04066 HIF-1 signaling pathway~ko04068 FoxO signaling pathway~ko04072 Phospholipase D signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04214 Apoptosis - fly~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04520 Adherens junction~ko04540 Gap junction~ko04630 JAK-STAT signaling pathway~ko04810 Regulation of actin cytoskeleton~ko04912 GnRH signaling pathway~ko04915 Estrogen signaling pathway~ko04921 Oxytocin signaling pathway~ko04926 Relaxin signaling pathway~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05120 Epithelial cell signaling in Helicobacter pylori~~ko05160 Hepatitis C~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~	,3190,3234,3215,3253,3193,2506,3243,3194,3259,3233,3174,3228,3183,3186,3166,2524,3217,3244,3172,3267,3230,3246,3227,3169,3240,3247,3212,3178,3248,3191,3179,3211,3238,3241,3231,3264,3181,3226,3188,3222,3185,3269,2510,3213,3261,3268,3182,3262,3218,3189,3176,3167,3229,3171,3219,3224,3232,3175,3170,2509,3252,3258,3370,3235,3254,3237,3256,3177,3251,3196,3223,3260,3214,3192,3263,3168,3245,3236,3242,3239,3257,3220,3225,3173,3221,3195,3184,2507,3216,3187,2508,3265,3255,3180,2712,3266	.	,3250,3249	0.999	-1.59	0.571	0.735	ID=COSV51766344;OCCURENCE=2(large_intestine),2(central_nervous_system),1(pancreas),104(lung),1(upper_aerodigestive_tract)	MU1314224	
7	55249005	55249005	G	T	EGFR	exonic	nonsynonymous SNV	ENSG00000146648	rs121913465	ENSG00000146648:ENST00000455089:exon19:c.G2168T:p.S723I,ENSG00000146648:ENST00000275493:exon20:c.G2303T:p.S768I,ENSG00000146648:ENST00000454757:exon20:c.G2144T:p.S715I	EGFR:NM_005228:exon20:c.G2303T:p.S768I	clinvar: Pathogenic 	 CancerVar: 11#Tier_I_strong EVS=[1, 0, 1, 1, 0, 0, 1, 1, 2, 2, 1, 1] 	.	.	.	.	6.143	28.4	0.002	5.85	0.992	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	EGFR:uc022ado.1:exon1:c.G8T:p.S3I,EGFR:uc010kzg.2:exon19:c.G2168T:p.S723I,EGFR:uc022adn.1:exon19:c.G2168T:p.S723I,EGFR:uc003tqk.3:exon20:c.G2303T:p.S768I,EGFR:uc011kco.2:exon20:c.G2144T:p.S715I,EGFR:uc022adm.1:exon20:c.G2303T:p.S768I	0.454	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	131550	211980;616069;	294023;	294023|-|<1 / 1 000 000|Autosomal recessive|Infancy<br>Neonatal|614328 616069 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04020 Calcium signaling pathway~ko04066 HIF-1 signaling pathway~ko04068 FoxO signaling pathway~ko04072 Phospholipase D signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04214 Apoptosis - fly~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04520 Adherens junction~ko04540 Gap junction~ko04630 JAK-STAT signaling pathway~ko04810 Regulation of actin cytoskeleton~ko04912 GnRH signaling pathway~ko04915 Estrogen signaling pathway~ko04921 Oxytocin signaling pathway~ko04926 Relaxin signaling pathway~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05120 Epithelial cell signaling in Helicobacter pylori~~ko05160 Hepatitis C~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~	,3234,3440,3458,3443,3446,3452,3215,3253,3454,2506,3243,3259,3233,3228,3217,3244,3267,3447,3230,3246,3453,3434,3227,3448,3240,3445,3247,3212,3248,3437,3460,3211,3238,3241,3231,3456,3264,3226,3222,3451,3444,3455,3269,2510,3213,3261,3268,3262,3218,3436,3229,3219,3224,3449,3232,3450,2509,3252,3258,3370,3235,3254,3237,3256,3435,3251,3223,3260,3214,3263,3442,3459,3245,3236,3242,3239,3257,3220,3439,3461,3225,3438,3221,3462,2507,3216,2508,3265,3441,3255,3457,2712,3266	.	,3250,3249	1.0	-1.7	0.698	1.995	ID=COSV51768106;OCCURENCE=1(breast),1(oesophagus),1(adrenal_gland),2(central_nervous_system),1(prostate),55(lung)	MU131498245	
7	148508727	148508727	T	A	EZH2	exonic	nonsynonymous SNV	ENSG00000106462	rs267601394	ENSG00000106462:ENST00000350995:exon15:c.A1805T:p.Y602F,ENSG00000106462:ENST00000476773:exon15:c.A1769T:p.Y590F,ENSG00000106462:ENST00000541220:exon15:c.A1769T:p.Y590F,ENSG00000106462:ENST00000320356:exon16:c.A1937T:p.Y646F,ENSG00000106462:ENST00000460911:exon16:c.A1922T:p.Y641F,ENSG00000106462:ENST00000478654:exon16:c.A1769T:p.Y590F,ENSG00000106462:ENST00000483967:exon16:c.A1895T:p.Y632F	EZH2:NM_001203249:exon15:c.A1769T:p.Y590F,EZH2:NM_152998:exon15:c.A1805T:p.Y602F,EZH2:NM_001203247:exon16:c.A1922T:p.Y641F,EZH2:NM_001203248:exon16:c.A1895T:p.Y632F,EZH2:NM_004456:exon16:c.A1937T:p.Y646F	clinvar: Likely_pathogenic 	 CancerVar: 11#Tier_I_strong EVS=[1, 0, 1, 1, 0, 0, 1, 1, 2, 2, 1, 1] 	.	.	.	.	6.643	32	0.006	5.63	1.000	.	.	CXC domain;SET domain	EZH2:uc022aov.1:exon13:c.A1679T:p.Y560F,EZH2:uc003wfc.2:exon15:c.A1805T:p.Y602F,EZH2:uc011kug.2:exon15:c.A1769T:p.Y590F,EZH2:uc003wfb.2:exon16:c.A1937T:p.Y646F,EZH2:uc003wfd.2:exon16:c.A1922T:p.Y641F,EZH2:uc011kuh.2:exon16:c.A1895T:p.Y632F	1.036	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	601573	277590;	3447;	3447|Camptodactyly-overgrowth-unusual facies syndrome|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal<br>Antenatal|277590 ~	.	,4880,4909,4910,4873,4871,4878,4882,4887	.	4877,4879,,4874,4875,4876,4881	0.999	-1.9	0.902	3.405	ID=COSV57445929;OCCURENCE=1(bone),89(haematopoietic_and_lymphoid_tissue),2(skin)	MU1372972	
7	148508728	148508728	A	G	EZH2	exonic	nonsynonymous SNV	ENSG00000106462	rs267601395	ENSG00000106462:ENST00000350995:exon15:c.T1804C:p.Y602H,ENSG00000106462:ENST00000476773:exon15:c.T1768C:p.Y590H,ENSG00000106462:ENST00000541220:exon15:c.T1768C:p.Y590H,ENSG00000106462:ENST00000320356:exon16:c.T1936C:p.Y646H,ENSG00000106462:ENST00000460911:exon16:c.T1921C:p.Y641H,ENSG00000106462:ENST00000478654:exon16:c.T1768C:p.Y590H,ENSG00000106462:ENST00000483967:exon16:c.T1894C:p.Y632H	EZH2:NM_001203249:exon15:c.T1768C:p.Y590H,EZH2:NM_152998:exon15:c.T1804C:p.Y602H,EZH2:NM_001203247:exon16:c.T1921C:p.Y641H,EZH2:NM_001203248:exon16:c.T1894C:p.Y632H,EZH2:NM_004456:exon16:c.T1936C:p.Y646H	clinvar: Likely_pathogenic 	 CancerVar: 11#Tier_I_strong EVS=[1, 0, 1, 1, 0, 0, 1, 1, 2, 2, 1, 1] 	.	.	.	.	6.744	32	0.0	5.52	1.000	.	.	CXC domain;SET domain	EZH2:uc022aov.1:exon13:c.T1678C:p.Y560H,EZH2:uc003wfc.2:exon15:c.T1804C:p.Y602H,EZH2:uc011kug.2:exon15:c.T1768C:p.Y590H,EZH2:uc003wfb.2:exon16:c.T1936C:p.Y646H,EZH2:uc003wfd.2:exon16:c.T1921C:p.Y641H,EZH2:uc011kuh.2:exon16:c.T1894C:p.Y632H	1.102	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	601573	277590;	3447;	3447|Camptodactyly-overgrowth-unusual facies syndrome|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal<br>Antenatal|277590 ~	.	,4880,4873,4888,4871,4878,4912,4882	.	4877,4879,,4874,4875,4876,4881	1.0	-1.98	0.945	4.605	ID=COSV57445793;OCCURENCE=1(salivary_gland),1(breast),1(biliary_tract),3(bone),27(haematopoietic_and_lymphoid_tissue),2(skin)	MU28727144	
7	148508728	148508728	A	T	EZH2	exonic	nonsynonymous SNV	ENSG00000106462	.	ENSG00000106462:ENST00000350995:exon15:c.T1804A:p.Y602N,ENSG00000106462:ENST00000476773:exon15:c.T1768A:p.Y590N,ENSG00000106462:ENST00000541220:exon15:c.T1768A:p.Y590N,ENSG00000106462:ENST00000320356:exon16:c.T1936A:p.Y646N,ENSG00000106462:ENST00000460911:exon16:c.T1921A:p.Y641N,ENSG00000106462:ENST00000478654:exon16:c.T1768A:p.Y590N,ENSG00000106462:ENST00000483967:exon16:c.T1894A:p.Y632N	EZH2:NM_001203249:exon15:c.T1768A:p.Y590N,EZH2:NM_152998:exon15:c.T1804A:p.Y602N,EZH2:NM_001203247:exon16:c.T1921A:p.Y641N,EZH2:NM_001203248:exon16:c.T1894A:p.Y632N,EZH2:NM_004456:exon16:c.T1936A:p.Y646N	clinvar: Likely_pathogenic 	 CancerVar: 11#Tier_I_strong EVS=[1, 0, 1, 1, 0, 0, 1, 1, 2, 2, 1, 1] 	.	.	.	.	6.764	32	0.0	5.52	1.000	.	.	CXC domain;SET domain	EZH2:uc022aov.1:exon13:c.T1678A:p.Y560N,EZH2:uc003wfc.2:exon15:c.T1804A:p.Y602N,EZH2:uc011kug.2:exon15:c.T1768A:p.Y590N,EZH2:uc003wfb.2:exon16:c.T1936A:p.Y646N,EZH2:uc003wfd.2:exon16:c.T1921A:p.Y641N,EZH2:uc011kuh.2:exon16:c.T1894A:p.Y632N	1.102	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	601573	277590;	3447;	3447|Camptodactyly-overgrowth-unusual facies syndrome|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal<br>Antenatal|277590 ~	.	,4880,4913,4890,4897,4914,4873,4896,4898,4892,4893,4894,4895,4899,4900,4871,4891,4878,4882	.	4877,4879,,4874,4875,4876,4881	0.999	-1.98	0.944	4.605	ID=COSV57445823;OCCURENCE=3(parathyroid),1(NS),79(haematopoietic_and_lymphoid_tissue),7(skin)	MU1477994	
7	148508727	148508727	T	G	EZH2	exonic	nonsynonymous SNV	ENSG00000106462	.	ENSG00000106462:ENST00000350995:exon15:c.A1805C:p.Y602S,ENSG00000106462:ENST00000476773:exon15:c.A1769C:p.Y590S,ENSG00000106462:ENST00000541220:exon15:c.A1769C:p.Y590S,ENSG00000106462:ENST00000320356:exon16:c.A1937C:p.Y646S,ENSG00000106462:ENST00000460911:exon16:c.A1922C:p.Y641S,ENSG00000106462:ENST00000478654:exon16:c.A1769C:p.Y590S,ENSG00000106462:ENST00000483967:exon16:c.A1895C:p.Y632S	EZH2:NM_001203249:exon15:c.A1769C:p.Y590S,EZH2:NM_152998:exon15:c.A1805C:p.Y602S,EZH2:NM_001203247:exon16:c.A1922C:p.Y641S,EZH2:NM_001203248:exon16:c.A1895C:p.Y632S,EZH2:NM_004456:exon16:c.A1937C:p.Y646S	clinvar: Likely_pathogenic 	 CancerVar: 11#Tier_I_strong EVS=[1, 0, 1, 1, 0, 0, 1, 1, 2, 2, 1, 1] 	.	.	.	.	6.692	32	0.016	5.63	1.000	.	.	CXC domain;SET domain	EZH2:uc022aov.1:exon13:c.A1679C:p.Y560S,EZH2:uc003wfc.2:exon15:c.A1805C:p.Y602S,EZH2:uc011kug.2:exon15:c.A1769C:p.Y590S,EZH2:uc003wfb.2:exon16:c.A1937C:p.Y646S,EZH2:uc003wfd.2:exon16:c.A1922C:p.Y641S,EZH2:uc011kuh.2:exon16:c.A1895C:p.Y632S	1.083	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	601573	277590;	3447;	3447|Camptodactyly-overgrowth-unusual facies syndrome|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal<br>Antenatal|277590 ~	.	,4880,4873,4915,4901,4905,4906,4902,4903,4871,4904,4907,4878,4882	.	4877,4879,,4874,4875,4876,4881	0.993	-1.94	0.923	4.605	ID=COSV57446054;OCCURENCE=42(haematopoietic_and_lymphoid_tissue),2(skin)	MU1634230	
4	1803564	1803564	C	T	FGFR3	exonic	nonsynonymous SNV	ENSG00000068078	rs121913482	ENSG00000068078:ENST00000507588:exon3:c.C202T:p.R68C,ENSG00000068078:ENST00000260795:exon6:c.C742T:p.R248C,ENSG00000068078:ENST00000352904:exon6:c.C742T:p.R248C,ENSG00000068078:ENST00000340107:exon7:c.C742T:p.R248C,ENSG00000068078:ENST00000412135:exon7:c.C742T:p.R248C,ENSG00000068078:ENST00000440486:exon7:c.C742T:p.R248C,ENSG00000068078:ENST00000481110:exon7:c.C742T:p.R248C	FGFR3:NM_000142:exon7:c.C742T:p.R248C,FGFR3:NM_001163213:exon7:c.C742T:p.R248C,FGFR3:NM_022965:exon7:c.C742T:p.R248C	clinvar: Pathogenic 	 CancerVar: 9#Tier_II_potential EVS=[1, 0, 0, 1, 0, 0, 1, 1, 2, 1, 1, 1] 	.	.	.	.	6.430	29.7	0.05	3.0	0.935	.	.	Immunoglobulin-like fold	FGFR3:uc003gdt.1:exon3:c.C268T:p.R90C,FGFR3:uc010icb.1:exon3:c.C268T:p.R90C,FGFR3:uc003gdq.3:exon7:c.C742T:p.R248C,FGFR3:uc003gdr.3:exon7:c.C742T:p.R248C,FGFR3:uc003gds.3:exon7:c.C742T:p.R248C,FGFR3:uc003gdu.2:exon7:c.C742T:p.R248C	0.938	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	134934	100800;109800;114500;146000;149730;162900;187600;187601;273300;602849;603956;610474;612247;616482;	85165;93262;85164;53271;363483;363494;363504;842;876;99865;2655;93274;1860;2655;79414;2363;429;15;	85165|SADDAN|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Childhood|616482 ~93262|Crouzon-dermoskeletal syndrome|Unknown|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal|612247 ~85164|CATSHL syndrome|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Autosomal recessive|Childhood|610474 ~53271|-|Unknown|Autosomal dominant|Infancy<br>Neonatal|602849 ~363483|Teratoma of the testis|<1 / 1 000 000|-|-|273300 ~363494|Non-dysgerminomatous germ cell tumor of testis<br>Testicular non seminomatous germ cell tumor<br>Testicular non-dysgerminomatous germ cell tumor|-|-|-|273300 ~363504|Testicular germ cell tumor|-|-|-|273300 ~842|Seminoma of testis<br>Seminomatous germ cell tumor of testis<br>Testicular seminoma|Unknown|Not applicable|Adult|273300 ~876|Endodermal sinus tumor|-|-|-|273300 ~99865|-|Unknown|Unknown|Adolescent<br>Adult|273300 ~2655|TD<br>Thanatophoric dwarfism|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal<br>Antenatal|156830 187600 187601 ~93274|Cloverleaf skull-micromelic bone dysplasia syndrome<br>TD2<br>Thanatophoric dwarfism type 2<br>Thanatophoric dwarfism-cloverleaf skull syndrome|Unknown|Autosomal dominant<br>or&nbsp;Not applicable|Infancy<br>Neonatal|156830 187601 ~1860|TD1<br>Thanatophoric dwarfism type 1|Unknown|Autosomal dominant<br>or&nbsp;Not applicable|Antenatal<br>Neonatal|187600 ~2655|TD<br>Thanatophoric dwarfism|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal<br>Antenatal|156830 187600 187601 ~79414|Wooly hair nevus|-|Not applicable|Neonatal<br>Infancy|162900 ~2363|LADD syndrome<br>LARD syndrome<br>Lacrimoauriculoradiodental syndrome<br>Levy-Hollister syndrome|<1 / 1 000 000|Autosomal dominant|Antenatal<br>Neonatal<br>Infancy<br>Childhood|149730 ~429|-|1-9 / 100 000|Autosomal dominant|Childhood|146000 ~15|-|1-9 / 100 000|Autosomal dominant|Neonatal|100800 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04810 Regulation of actin cytoskeleton~ko05200 Pathways in cancer~ko05206 MicroRNAs in cancer~ko05219 Bladder cancer~ko05230 Central carbon metabolism in cancer~	5505,,5500,5469,5502,5487,5475,5478,5501,5476,5471,5481,5486,5483,5482,5472,5470,5479,5477,5488,5499,5498,5485,5506,5473,5497,5504,5484,5503,5480,5474	.	.	1.0	-1.37	0.799	4.01	ID=COSV53390662;OCCURENCE=1(breast),2(haematopoietic_and_lymphoid_tissue),215(urinary_tract),73(skin),3(lung),4(upper_aerodigestive_tract)	MU1296398	
4	1803568	1803568	C	G	FGFR3	exonic	nonsynonymous SNV	ENSG00000068078	rs121913483	ENSG00000068078:ENST00000507588:exon3:c.C206G:p.S69C,ENSG00000068078:ENST00000260795:exon6:c.C746G:p.S249C,ENSG00000068078:ENST00000352904:exon6:c.C746G:p.S249C,ENSG00000068078:ENST00000340107:exon7:c.C746G:p.S249C,ENSG00000068078:ENST00000412135:exon7:c.C746G:p.S249C,ENSG00000068078:ENST00000440486:exon7:c.C746G:p.S249C,ENSG00000068078:ENST00000481110:exon7:c.C746G:p.S249C	FGFR3:NM_000142:exon7:c.C746G:p.S249C,FGFR3:NM_001163213:exon7:c.C746G:p.S249C,FGFR3:NM_022965:exon7:c.C746G:p.S249C	clinvar: Pathogenic 	 CancerVar: 9#Tier_II_potential EVS=[1, 0, 0, 1, 0, 0, 1, 1, 2, 1, 1, 1] 	9.654e-06	.	.	.	3.567	23.1	0.045	3.94	0.928	.	.	.	FGFR3:uc003gdt.1:exon3:c.C272G:p.S91C,FGFR3:uc010icb.1:exon3:c.C272G:p.S91C,FGFR3:uc003gdq.3:exon7:c.C746G:p.S249C,FGFR3:uc003gdr.3:exon7:c.C746G:p.S249C,FGFR3:uc003gds.3:exon7:c.C746G:p.S249C,FGFR3:uc003gdu.2:exon7:c.C746G:p.S249C	0.799	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	134934	100800;109800;114500;146000;149730;162900;187600;187601;273300;602849;603956;610474;612247;616482;	85165;93262;85164;53271;363483;363494;363504;842;876;99865;2655;93274;1860;2655;79414;2363;429;15;	85165|SADDAN|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Childhood|616482 ~93262|Crouzon-dermoskeletal syndrome|Unknown|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal|612247 ~85164|CATSHL syndrome|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Autosomal recessive|Childhood|610474 ~53271|-|Unknown|Autosomal dominant|Infancy<br>Neonatal|602849 ~363483|Teratoma of the testis|<1 / 1 000 000|-|-|273300 ~363494|Non-dysgerminomatous germ cell tumor of testis<br>Testicular non seminomatous germ cell tumor<br>Testicular non-dysgerminomatous germ cell tumor|-|-|-|273300 ~363504|Testicular germ cell tumor|-|-|-|273300 ~842|Seminoma of testis<br>Seminomatous germ cell tumor of testis<br>Testicular seminoma|Unknown|Not applicable|Adult|273300 ~876|Endodermal sinus tumor|-|-|-|273300 ~99865|-|Unknown|Unknown|Adolescent<br>Adult|273300 ~2655|TD<br>Thanatophoric dwarfism|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal<br>Antenatal|156830 187600 187601 ~93274|Cloverleaf skull-micromelic bone dysplasia syndrome<br>TD2<br>Thanatophoric dwarfism type 2<br>Thanatophoric dwarfism-cloverleaf skull syndrome|Unknown|Autosomal dominant<br>or&nbsp;Not applicable|Infancy<br>Neonatal|156830 187601 ~1860|TD1<br>Thanatophoric dwarfism type 1|Unknown|Autosomal dominant<br>or&nbsp;Not applicable|Antenatal<br>Neonatal|187600 ~2655|TD<br>Thanatophoric dwarfism|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal<br>Antenatal|156830 187600 187601 ~79414|Wooly hair nevus|-|Not applicable|Neonatal<br>Infancy|162900 ~2363|LADD syndrome<br>LARD syndrome<br>Lacrimoauriculoradiodental syndrome<br>Levy-Hollister syndrome|<1 / 1 000 000|Autosomal dominant|Antenatal<br>Neonatal<br>Infancy<br>Childhood|149730 ~429|-|1-9 / 100 000|Autosomal dominant|Childhood|146000 ~15|-|1-9 / 100 000|Autosomal dominant|Neonatal|100800 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04810 Regulation of actin cytoskeleton~ko05200 Pathways in cancer~ko05206 MicroRNAs in cancer~ko05219 Bladder cancer~ko05230 Central carbon metabolism in cancer~	,5469,5532,5524,5528,5487,5475,5478,5476,5515,5514,5471,5481,5527,5486,5483,5525,5482,5526,5472,5530,5519,5521,5470,5518,5529,5517,5522,5479,5477,5488,5511,5533,5534,5498,5520,5485,5512,5513,5516,5523,5531,5473,5497,5510,5484,5480,5474	.	.	1.0	-1.32	0.771	3.305	ID=COSV53390026;OCCURENCE=7(cervix),3(vulva),3(ovary),1438(urinary_tract),27(skin),7(lung),24(upper_aerodigestive_tract),2(thymus)	MU1305116	
4	1806099	1806099	A	G	FGFR3	exonic	nonsynonymous SNV	ENSG00000068078	rs121913485	ENSG00000068078:ENST00000260795:exon8:c.A1118G:p.Y373C,ENSG00000068078:ENST00000340107:exon9:c.A1124G:p.Y375C,ENSG00000068078:ENST00000440486:exon9:c.A1118G:p.Y373C,ENSG00000068078:ENST00000481110:exon9:c.A1118G:p.Y373C	FGFR3:NM_000142:exon9:c.A1118G:p.Y373C,FGFR3:NM_001163213:exon9:c.A1124G:p.Y375C	clinvar: Pathogenic 	 CancerVar: 10#Tier_II_potential EVS=[1, 1, 0, 1, 0, 0, 1, 1, 2, 1, 1, 1] 	.	.	.	.	3.448	23.0	0.003	1.93	0.948	.	.	.	FGFR3:uc003gdq.3:exon9:c.A1118G:p.Y373C,FGFR3:uc003gdr.3:exon9:c.A1118G:p.Y373C,FGFR3:uc003gdu.2:exon9:c.A1124G:p.Y375C	0.732	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	134934	100800;109800;114500;146000;149730;162900;187600;187601;273300;602849;603956;610474;612247;616482;	85165;93262;85164;53271;363483;363494;363504;842;876;99865;2655;93274;1860;2655;79414;2363;429;15;	85165|SADDAN|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Childhood|616482 ~93262|Crouzon-dermoskeletal syndrome|Unknown|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal|612247 ~85164|CATSHL syndrome|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Autosomal recessive|Childhood|610474 ~53271|-|Unknown|Autosomal dominant|Infancy<br>Neonatal|602849 ~363483|Teratoma of the testis|<1 / 1 000 000|-|-|273300 ~363494|Non-dysgerminomatous germ cell tumor of testis<br>Testicular non seminomatous germ cell tumor<br>Testicular non-dysgerminomatous germ cell tumor|-|-|-|273300 ~363504|Testicular germ cell tumor|-|-|-|273300 ~842|Seminoma of testis<br>Seminomatous germ cell tumor of testis<br>Testicular seminoma|Unknown|Not applicable|Adult|273300 ~876|Endodermal sinus tumor|-|-|-|273300 ~99865|-|Unknown|Unknown|Adolescent<br>Adult|273300 ~2655|TD<br>Thanatophoric dwarfism|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal<br>Antenatal|156830 187600 187601 ~93274|Cloverleaf skull-micromelic bone dysplasia syndrome<br>TD2<br>Thanatophoric dwarfism type 2<br>Thanatophoric dwarfism-cloverleaf skull syndrome|Unknown|Autosomal dominant<br>or&nbsp;Not applicable|Infancy<br>Neonatal|156830 187601 ~1860|TD1<br>Thanatophoric dwarfism type 1|Unknown|Autosomal dominant<br>or&nbsp;Not applicable|Antenatal<br>Neonatal|187600 ~2655|TD<br>Thanatophoric dwarfism|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal<br>Antenatal|156830 187600 187601 ~79414|Wooly hair nevus|-|Not applicable|Neonatal<br>Infancy|162900 ~2363|LADD syndrome<br>LARD syndrome<br>Lacrimoauriculoradiodental syndrome<br>Levy-Hollister syndrome|<1 / 1 000 000|Autosomal dominant|Antenatal<br>Neonatal<br>Infancy<br>Childhood|149730 ~429|-|1-9 / 100 000|Autosomal dominant|Childhood|146000 ~15|-|1-9 / 100 000|Autosomal dominant|Neonatal|100800 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04810 Regulation of actin cytoskeleton~ko05200 Pathways in cancer~ko05206 MicroRNAs in cancer~ko05219 Bladder cancer~ko05230 Central carbon metabolism in cancer~	,5554,5469,5561,5487,5475,5478,5560,5476,5553,5471,5481,5486,5556,5483,5482,5566,5472,5562,5470,5567,5479,5563,5569,5552,5477,5488,5557,5498,5485,5558,5568,5551,5473,5497,5484,5559,5565,5555,5480,5474	,5564	.	0.999	-2.35	0.782	2.595	ID=COSV53390174;OCCURENCE=1(biliary_tract),8(haematopoietic_and_lymphoid_tissue),2(kidney),446(urinary_tract),16(skin),1(upper_aerodigestive_tract),1(thymus)	MU4618837	
9	5073770	5073770	G	T	JAK2	exonic	nonsynonymous SNV	ENSG00000096968	rs77375493	ENSG00000096968:ENST00000544510:exon11:c.G1402T:p.V468F,ENSG00000096968:ENST00000539801:exon13:c.G1849T:p.V617F,ENSG00000096968:ENST00000381652:exon14:c.G1849T:p.V617F	JAK2:NM_004972:exon14:c.G1849T:p.V617F	clinvar: Pathogenic 	 CancerVar: 11#Tier_I_strong EVS=[1, 1, 1, 1, 0, 0, 0, 1, 2, 2, 1, 1] 	0.0007	0.0002	.	0.0002	6.874	33	0.002	5.51	1.000	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	JAK2:uc010mhm.3:exon13:c.G1849T:p.V617F,JAK2:uc003ziw.3:exon14:c.G1849T:p.V617F	0.442	AFR:0.0002,AMR:0,EAS:0.0006,FIN:0.0003,NFE:0.0002,OTH:0,ASJ:0	147796	133100;254450;263300;600800;601626;614521;	3318;71493;519;729;824;90042;	3318|ET<br>Essential thrombocytosis|1-5 / 10 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|187950 601977 614521 ~71493|Familial thrombocythemia<br>Hereditary thrombocythemia|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;X-linked recessive|Childhood|187950 300331 601977 614521 ~519|AML<br>Acute myelogenous leukemia|1-9 / 100 000|-|All ages|601626 ~729|Acquired primary erythrocytosis<br>Osler-Vaquez disease<br>PV<br>Polycythemia rubra vera<br>Vaquez disease|1-5 / 10 000|Not applicable|All ages|263300 ~824|Agnogenic myeloid metaplasia<br>Idiopathic myelofibrosis<br>Myelofibrosis with myeloid metaplasia<br>Osteomyelofibrosis|1-9 / 100 000|-|Adult|254450 ~90042|Congenital erythrocytosis due to erythropoietin receptor mutation<br>Congenital polycythemia due to erythropoietin receptor mutation<br>Familial erythrocytosis<br>PFCP<br>Primary congenital erythrocytosis<br>Primary familial and congenital polycythemia|Unknown|Autosomal dominant|All ages|133100 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko04062 Chemokine signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04217 Necroptosis~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04630 JAK-STAT signaling pathway~ko04658 Th1 and Th2 cell differentiation~ko04659 Th17 cell differentiation~ko04725 Cholinergic synapse~ko04917 Prolactin signaling pathway~ko04920 Adipocytokine signaling pathway~ko04933 AGE-RAGE signaling pathway in diabetic complications~ko05140 Leishmaniasis~ko05145 Toxoplasmosis~ko05152 Tuberculosis~ko05161 Hepatitis B~ko05164 Influenza A~ko05167 Kaposi sarcoma-associated herpesvirus infection~ko05168 Herpes simplex virus 1 infection~ko05200 Pathways in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~	,6227,6236,6239,6230,6247,6223,6250,6248,6240,6246,6241,6228,6244,6233,6235,6226,6238,6225,6232,6224,6229,6214,6222,6231,6249,6245	6234,6237,6242,	,6243	0.996	-1.69	0.681	2	ID=COSV67569051;OCCURENCE=1(liver),1(central_nervous_system),1(NS),41923(haematopoietic_and_lymphoid_tissue),3(lung),1(thyroid)	MU599827	
4	55602664	55602664	G	C	KIT	exonic	nonsynonymous SNV	ENSG00000157404	.	ENSG00000157404:ENST00000288135:exon18:c.G2485C:p.A829P,ENSG00000157404:ENST00000412167:exon18:c.G2473C:p.A825P	KIT:NM_000222:exon18:c.G2485C:p.A829P,KIT:NM_001093772:exon18:c.G2473C:p.A825P	clinvar: Pathogenic/Likely_pathogenic 	 CancerVar: 9#Tier_II_potential EVS=[1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1] 	.	.	.	.	5.548	26.4	0.002	5.7	0.142	0.9990	0.954	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	KIT:uc010igr.3:exon18:c.G2485C:p.A829P,KIT:uc010igs.3:exon18:c.G2473C:p.A825P	0.220	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164920	154800;172800;273300;601626;606764;	44890;519;363483;363494;363504;842;876;99865;2884;79457;98292;	44890|GIST<br>Gastrointestinal stromal sarcoma|1-5 / 10 000|Not applicable<br>or&nbsp;Autosomal dominant|Childhood<br>Adolescent<br>Adult|606764 ~519|AML<br>Acute myelogenous leukemia|1-9 / 100 000|-|All ages|601626 ~363483|Teratoma of the testis|<1 / 1 000 000|-|-|273300 ~363494|Non-dysgerminomatous germ cell tumor of testis<br>Testicular non seminomatous germ cell tumor<br>Testicular non-dysgerminomatous germ cell tumor|-|-|-|273300 ~363504|Testicular germ cell tumor|-|-|-|273300 ~842|Seminoma of testis<br>Seminomatous germ cell tumor of testis<br>Testicular seminoma|Unknown|Not applicable|Adult|273300 ~876|Endodermal sinus tumor|-|-|-|273300 ~99865|-|Unknown|Unknown|Adolescent<br>Adult|273300 ~2884|-|Unknown|Autosomal dominant|Infancy<br>Neonatal|172800 ~79457|Urticaria pigmentosa|Unknown|Not applicable|All ages|154800 ~98292|-|1-9 / 100 000|-|All ages|154800 ~	~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04072 Phospholipase D signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04640 Hematopoietic cell lineage~ko04916 Melanogenesis~ko05200 Pathways in cancer~ko05221 Acute myeloid leukemia~ko05224 Breast cancer~ko05230 Central carbon metabolism in cancer~	6591,6635,6633,,6589,6587,6372,6584,6361,6377,6582,6599,6381,6588,6611,6379,6590,6380,6634,6375,6610,6373,6376,6371,6374,6362,6583,6585,6592,6378,6370	6586,	.	0.992	-2.5	0.643	0.28	ID=COSV55414160;OCCURENCE=1(soft_tissue),1(genital_tract),3(testis)	.	
4	55595519	55595519	C	T	KIT	exonic	nonsynonymous SNV	ENSG00000157404	rs121913516	ENSG00000157404:ENST00000288135:exon14:c.C2009T:p.T670I,ENSG00000157404:ENST00000412167:exon14:c.C1997T:p.T666I	KIT:NM_000222:exon14:c.C2009T:p.T670I,KIT:NM_001093772:exon14:c.C1997T:p.T666I	clinvar: Likely_pathogenic 	 CancerVar: 9#Tier_II_potential EVS=[1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1] 	.	.	.	3.23e-05	6.958	33	0.0	5.93	0.983	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	KIT:uc010igt.2:exon4:c.C356T:p.T119I,KIT:uc010igr.3:exon14:c.C2009T:p.T670I,KIT:uc010igs.3:exon14:c.C1997T:p.T666I	0.587	AFR:0,AMR:0,EAS:0,FIN:0.0003,NFE:0,OTH:0,ASJ:0	164920	154800;172800;273300;601626;606764;	44890;519;363483;363494;363504;842;876;99865;2884;79457;98292;	44890|GIST<br>Gastrointestinal stromal sarcoma|1-5 / 10 000|Not applicable<br>or&nbsp;Autosomal dominant|Childhood<br>Adolescent<br>Adult|606764 ~519|AML<br>Acute myelogenous leukemia|1-9 / 100 000|-|All ages|601626 ~363483|Teratoma of the testis|<1 / 1 000 000|-|-|273300 ~363494|Non-dysgerminomatous germ cell tumor of testis<br>Testicular non seminomatous germ cell tumor<br>Testicular non-dysgerminomatous germ cell tumor|-|-|-|273300 ~363504|Testicular germ cell tumor|-|-|-|273300 ~842|Seminoma of testis<br>Seminomatous germ cell tumor of testis<br>Testicular seminoma|Unknown|Not applicable|Adult|273300 ~876|Endodermal sinus tumor|-|-|-|273300 ~99865|-|Unknown|Unknown|Adolescent<br>Adult|273300 ~2884|-|Unknown|Autosomal dominant|Infancy<br>Neonatal|172800 ~79457|Urticaria pigmentosa|Unknown|Not applicable|All ages|154800 ~98292|-|1-9 / 100 000|-|All ages|154800 ~	~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04072 Phospholipase D signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04640 Hematopoietic cell lineage~ko04916 Melanogenesis~ko05200 Pathways in cancer~ko05221 Acute myeloid leukemia~ko05224 Breast cancer~ko05230 Central carbon metabolism in cancer~	6591,6635,6348,6633,6667,6346,,6658,6358,6589,6587,6584,6582,6659,6666,6657,6671,6349,6664,6381,6347,6670,6588,6611,6379,6668,6660,6672,6590,6380,6350,6634,6662,6351,6669,6610,6663,6344,6656,6583,6345,6665,6585,6592,6661	6586,	.	1.0	-2.53	0.736	0.79	ID=COSV55410040;OCCURENCE=6(soft_tissue),2(skin)	.	
4	55594258	55594258	T	C	KIT	exonic	nonsynonymous SNV	ENSG00000157404	rs121913523	ENSG00000157404:ENST00000288135:exon13:c.T1961C:p.V654A,ENSG00000157404:ENST00000412167:exon13:c.T1949C:p.V650A	KIT:NM_000222:exon13:c.T1961C:p.V654A,KIT:NM_001093772:exon13:c.T1949C:p.V650A	clinvar: Pathogenic/Likely_pathogenic 	 CancerVar: 11#Tier_I_strong EVS=[1, 1, 0, 1, 0, 0, 1, 1, 2, 2, 1, 1] 	.	.	.	.	5.700	26.8	0.021	6.06	0.995	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain;Tyrosine-protein kinase, receptor class III, conserved site	KIT:uc010igt.2:exon3:c.T308C:p.V103A,KIT:uc010igr.3:exon13:c.T1961C:p.V654A,KIT:uc010igs.3:exon13:c.T1949C:p.V650A	0.818	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164920	154800;172800;273300;601626;606764;	44890;519;363483;363494;363504;842;876;99865;2884;79457;98292;	44890|GIST<br>Gastrointestinal stromal sarcoma|1-5 / 10 000|Not applicable<br>or&nbsp;Autosomal dominant|Childhood<br>Adolescent<br>Adult|606764 ~519|AML<br>Acute myelogenous leukemia|1-9 / 100 000|-|All ages|601626 ~363483|Teratoma of the testis|<1 / 1 000 000|-|-|273300 ~363494|Non-dysgerminomatous germ cell tumor of testis<br>Testicular non seminomatous germ cell tumor<br>Testicular non-dysgerminomatous germ cell tumor|-|-|-|273300 ~363504|Testicular germ cell tumor|-|-|-|273300 ~842|Seminoma of testis<br>Seminomatous germ cell tumor of testis<br>Testicular seminoma|Unknown|Not applicable|Adult|273300 ~876|Endodermal sinus tumor|-|-|-|273300 ~99865|-|Unknown|Unknown|Adolescent<br>Adult|273300 ~2884|-|Unknown|Autosomal dominant|Infancy<br>Neonatal|172800 ~79457|Urticaria pigmentosa|Unknown|Not applicable|All ages|154800 ~98292|-|1-9 / 100 000|-|All ages|154800 ~	~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04072 Phospholipase D signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04640 Hematopoietic cell lineage~ko04916 Melanogenesis~ko05200 Pathways in cancer~ko05221 Acute myeloid leukemia~ko05224 Breast cancer~ko05230 Central carbon metabolism in cancer~	6591,6635,6633,,6341,6589,6587,6737,6584,6582,6336,6339,6727,6356,6732,6734,6729,6736,6726,6381,6340,6588,6611,6379,6337,6342,6733,6590,6380,6634,6731,6728,6489,6490,6491,6725,6610,6357,6730,6343,6583,6735,6585,6592,6338	6586,	.	0.789	-3.11	0.836	2.285	ID=COSV55389496;OCCURENCE=1(haematopoietic_and_lymphoid_tissue),46(soft_tissue)	MU55852071	
4	55599341	55599341	T	G	KIT	exonic	nonsynonymous SNV	ENSG00000157404	.	ENSG00000157404:ENST00000288135:exon17:c.T2467G:p.Y823D,ENSG00000157404:ENST00000412167:exon17:c.T2455G:p.Y819D	KIT:NM_000222:exon17:c.T2467G:p.Y823D,KIT:NM_001093772:exon17:c.T2455G:p.Y819D	clinvar: Likely_pathogenic 	 CancerVar: 10#Tier_II_potential EVS=[1, 1, 0, 1, 0, 0, 1, 1, 1, 2, 1, 1] 	.	.	.	.	6.923	33	0.0	5.47	1.000	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	KIT:uc010igr.3:exon17:c.T2467G:p.Y823D,KIT:uc010igs.3:exon17:c.T2455G:p.Y819D	0.588	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164920	154800;172800;273300;601626;606764;	44890;519;363483;363494;363504;842;876;99865;2884;79457;98292;	44890|GIST<br>Gastrointestinal stromal sarcoma|1-5 / 10 000|Not applicable<br>or&nbsp;Autosomal dominant|Childhood<br>Adolescent<br>Adult|606764 ~519|AML<br>Acute myelogenous leukemia|1-9 / 100 000|-|All ages|601626 ~363483|Teratoma of the testis|<1 / 1 000 000|-|-|273300 ~363494|Non-dysgerminomatous germ cell tumor of testis<br>Testicular non seminomatous germ cell tumor<br>Testicular non-dysgerminomatous germ cell tumor|-|-|-|273300 ~363504|Testicular germ cell tumor|-|-|-|273300 ~842|Seminoma of testis<br>Seminomatous germ cell tumor of testis<br>Testicular seminoma|Unknown|Not applicable|Adult|273300 ~876|Endodermal sinus tumor|-|-|-|273300 ~99865|-|Unknown|Unknown|Adolescent<br>Adult|273300 ~2884|-|Unknown|Autosomal dominant|Infancy<br>Neonatal|172800 ~79457|Urticaria pigmentosa|Unknown|Not applicable|All ages|154800 ~98292|-|1-9 / 100 000|-|All ages|154800 ~	~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04072 Phospholipase D signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04640 Hematopoietic cell lineage~ko04916 Melanogenesis~ko05200 Pathways in cancer~ko05221 Acute myeloid leukemia~ko05224 Breast cancer~ko05230 Central carbon metabolism in cancer~	6591,6635,6348,6633,,6346,6589,6587,6762,6584,6599,6582,6349,6763,6381,6598,6359,6522,6347,6360,6588,6611,6379,6497,6494,6590,6380,6350,6495,6634,6609,6521,6496,6596,6351,6764,6610,6765,6344,6583,6345,6597,6585,6592,6595	6586,	.	1.0	-1.86	0.728	2.105	ID=COSV55388545;OCCURENCE=1(genital_tract),1(large_intestine),1(haematopoietic_and_lymphoid_tissue),7(soft_tissue),11(testis)	.	
4	55599321	55599321	A	T	KIT	exonic	nonsynonymous SNV	ENSG00000157404	rs121913507	ENSG00000157404:ENST00000288135:exon17:c.A2447T:p.D816V,ENSG00000157404:ENST00000412167:exon17:c.A2435T:p.D812V	KIT:NM_000222:exon17:c.A2447T:p.D816V,KIT:NM_001093772:exon17:c.A2435T:p.D812V	clinvar: Uncertain_significance 	 CancerVar: 9#Tier_II_potential EVS=[1, 1, 0, 1, 0, 0, 1, 0, 2, 1, 1, 1] 	.	.	.	.	6.511	31	0.0	5.62	1.000	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	KIT:uc010igr.3:exon17:c.A2447T:p.D816V,KIT:uc010igs.3:exon17:c.A2435T:p.D812V	0.303	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164920	154800;172800;273300;601626;606764;	44890;519;363483;363494;363504;842;876;99865;2884;79457;98292;	44890|GIST<br>Gastrointestinal stromal sarcoma|1-5 / 10 000|Not applicable<br>or&nbsp;Autosomal dominant|Childhood<br>Adolescent<br>Adult|606764 ~519|AML<br>Acute myelogenous leukemia|1-9 / 100 000|-|All ages|601626 ~363483|Teratoma of the testis|<1 / 1 000 000|-|-|273300 ~363494|Non-dysgerminomatous germ cell tumor of testis<br>Testicular non seminomatous germ cell tumor<br>Testicular non-dysgerminomatous germ cell tumor|-|-|-|273300 ~363504|Testicular germ cell tumor|-|-|-|273300 ~842|Seminoma of testis<br>Seminomatous germ cell tumor of testis<br>Testicular seminoma|Unknown|Not applicable|Adult|273300 ~876|Endodermal sinus tumor|-|-|-|273300 ~99865|-|Unknown|Unknown|Adolescent<br>Adult|273300 ~2884|-|Unknown|Autosomal dominant|Infancy<br>Neonatal|172800 ~79457|Urticaria pigmentosa|Unknown|Not applicable|All ages|154800 ~98292|-|1-9 / 100 000|-|All ages|154800 ~	~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04072 Phospholipase D signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04640 Hematopoietic cell lineage~ko04916 Melanogenesis~ko05200 Pathways in cancer~ko05221 Acute myeloid leukemia~ko05224 Breast cancer~ko05230 Central carbon metabolism in cancer~	6591,6635,6348,6633,,6346,6414,6589,6401,6587,6406,6405,6584,6425,6411,6599,6582,6427,6349,6402,6419,6416,6381,6422,6428,6417,6598,6359,6434,6522,6347,6360,6588,6611,6379,6409,6497,6420,6423,6494,6429,6590,6435,6424,6380,6350,6495,6634,6609,6426,6431,6410,6521,6496,6596,6412,6351,6610,6413,6403,6404,6418,6415,6432,6344,6583,6345,6597,6407,6585,6421,6430,6592,6433,6595	6586,	6408,,6436	0.998	-1.74	0.562	0.63	ID=COSV55386424;OCCURENCE=6(genital_tract),1(cervix),6(ovary),1(NS),814(haematopoietic_and_lymphoid_tissue),3(skin),22(testis)	MU820931	
12	25398285	25398285	C	A	KRAS	exonic	nonsynonymous SNV	ENSG00000133703	rs121913530	ENSG00000133703:ENST00000256078:exon2:c.G34T:p.G12C,ENSG00000133703:ENST00000311936:exon2:c.G34T:p.G12C,ENSG00000133703:ENST00000556131:exon2:c.G34T:p.G12C,ENSG00000133703:ENST00000557334:exon2:c.G34T:p.G12C	KRAS:NM_004985:exon2:c.G34T:p.G12C,KRAS:NM_033360:exon2:c.G34T:p.G12C	clinvar: Pathogenic/Likely_pathogenic 	 CancerVar: 11#Tier_I_strong EVS=[1, 1, 1, 1, 0, 0, 1, 1, 2, 1, 1, 1] 	1.976e-05	.	.	.	7.016	33	0.02	5.68	1.000	.	.	P-loop containing nucleoside triphosphate hydrolase;Small GTP-binding protein domain	KRAS:uc001rgp.1:exon2:c.G34T:p.G12C,KRAS:uc001rgq.1:exon2:c.G34T:p.G12C	0.548	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	190070	109800;114480;137215;163200;211980;260350;601626;609942;614470;615278;	1340;268114;648;519;1333;2612;26106;227535;	1340|CFC syndrome|Unknown|Autosomal dominant|Antenatal<br>Neonatal|115150 615278 615279 615280 ~268114|ALPS type 4<br>ALPS type IV<br>Autoimmune lymphoproliferative syndrome type 4<br>Autoimmune lymphoproliferative syndrome type IV<br>RALD|<1 / 1 000 000|Unknown|Childhood<br>Infancy|614470 ~648|-|Unknown|Autosomal dominant|Neonatal|163950 605275 609942 610733 611553 613224 613706 615355 616559 616564 ~519|AML<br>Acute myelogenous leukemia|1-9 / 100 000|-|All ages|601626 ~1333|Familial pancreatic cancer|1-9 / 1 000 000|Multigenic/multifactorial|Adult|260350 606856 613347 613348 614320 ~2612|Nevus sebaceus of Jadassohn<br>Nevus sebaceus syndrome<br>Organoid nevus syndrome<br>Schimmelpenning syndrome<br>Solomon syndrome|Unknown|Not applicable|Childhood|163200 ~26106|FDGC<br>Familial diffuse cancer of stomach<br>Familial diffuse gastric cancer<br>HDGC<br>Hereditary diffuse cancer of stomach<br>Hereditary diffuse gastric adenocarcinoma|Unknown|Autosomal dominant|Adult|137215 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04062 Chemokine signaling pathway~ko04068 FoxO signaling pathway~ko04071 Sphingolipid signaling pathway~ko04072 Phospholipase D signaling pathway~ko04113 Meiosis - yeast~ko04137 Mitophagy - animal~ko04138 Autophagy - yeast~ko04140 Autophagy - animal~ko04150 mTOR signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04210 Apoptosis~ko04211 Longevity regulating pathway~ko04213 Longevity regulating pathway - multiple species~ko04214 Apoptosis - fly~ko04218 Cellular senescence~ko04320 Dorso-ventral axis formation~ko04360 Axon guidance~ko04370 VEGF signaling pathway~ko04371 Apelin signaling pathway~ko04540 Gap junction~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04625 C-type lectin receptor signaling pathway~ko04650 Natural killer cell mediated cytotoxicity~ko04660 T cell receptor signaling pathway~ko04662 B cell receptor signaling pathway~ko04664 Fc epsilon RI signaling pathway~ko04714 Thermogenesis~ko04720 Long-term potentiation~ko04722 Neurotrophin signaling pathway~ko04725 Cholinergic synapse~ko04726 Serotonergic synapse~ko04730 Long-term depression~ko04810 Regulation of actin cytoskeleton~ko04910 Insulin signaling pathway~ko04912 GnRH signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04915 Estrogen signaling pathway~ko04916 Melanogenesis~ko04917 Prolactin signaling pathway~ko04919 Thyroid hormone signaling pathway~ko04921 Oxytocin signaling pathway~ko04926 Relaxin signaling pathway~ko04929 GnRH secretion~ko04933 AGE-RAGE signaling pathway in diabetic complications~ko04960 Aldosterone-regulated sodium reabsorption~ko05034 Alcoholism~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05166 Human T-cell leukemia virus 1 infection~ko05167 Kaposi sarcoma-associated herpesvirus infection~ko05170 Human immunodeficiency virus 1 infection~ko05200 Pathways in cancer~ko05203 Viral carcinogenesis~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05216 Thyroid cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~	7035,,7033,7019,6846,6998,6874,7049,7025,6843,7004,7028,7051,7015,6877,6885,7062,7059,7050,7023,6889,7048,7008,7045,6814,7032,7061,6838,7010,7022,7064,6886,7041,7002,6849,6851,6835,7031,6842,7009,7056,6847,7060,6875,7017,6841,7039,7029,7044,7000,6879,7057,7007,6840,6881,6844,7040,7027,7005,7037,7052,6890,7030,6882,6850,7016,6845,7001,7014,7043,7047,6999,7055,6848,6836,7034,7038,7018,7012,7058,7006,6815,7063,7042,6878,7024,6839,6888,7013,7046,6876,7053,7036,7054,6887,7003,6880,6837,6997,7021	,6883	,7020,7026,6884,7011	1.0	-1.24	0.701	3.135	ID=COSV55497469;OCCURENCE=13(breast),2(penis),7(liver),11(peritoneum),3(oesophagus),1(genital_tract),1(adrenal_gland),8(cervix),2065(large_intestine),1(central_nervous_system),66(biliary_tract),46(ovary),20(NS),29(haematopoietic_and_lymphoid_tissue),18(stomach),18(urinary_tract),18(soft_tissue),5(kidney),190(pancreas),4(gastrointestinal_tract_(site_indeterminate)),8(skin),10(prostate),2607(lung),20(thyroid),9(upper_aerodigestive_tract),4(testis),19(small_intestine),63(endometrium)	MU22774	
4	55152093	55152093	A	T	PDGFRA	exonic	nonsynonymous SNV	ENSG00000134853;ENSG00000145216	rs121908585	ENSG00000134853:ENST00000257290:exon18:c.A2525T:p.D842V,ENSG00000145216:ENST00000507166:exon19:c.A1805T:p.D602V	PDGFRA:NM_006206:exon18:c.A2525T:p.D842V	clinvar: Pathogenic 	 CancerVar: 9#Tier_II_potential EVS=[1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1] 	.	.	.	.	6.552	31	0.001	5.85	1.000	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	PDGFRA:uc003han.4:exon18:c.A2525T:p.D842V,PDGFRA:uc003haa.3:exon19:c.A1805T:p.D602V	0.265	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	173490	606764;607685;	3260;44890;	3260|-|Unknown|-|Adult|607685 ~44890|GIST<br>Gastrointestinal stromal sarcoma|1-5 / 10 000|Not applicable<br>or&nbsp;Autosomal dominant|Childhood<br>Adolescent<br>Adult|606764 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04020 Calcium signaling pathway~ko04072 Phospholipase D signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04510 Focal adhesion~ko04540 Gap junction~ko04630 JAK-STAT signaling pathway~ko04810 Regulation of actin cytoskeleton~ko05163 Human cytomegalovirus infection~ko05200 Pathways in cancer~ko05206 MicroRNAs in cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~	,8491,8485,8499,8506,8495,8492,8496,8510,8511,8503,8498,8497,8502,8512,8513,8517,8524,8564,8514,8515,8557,8501,8500,8488,8522,8505,8507,8494,8525,8508,8516,8509,8486,8520,8519,8487,8518,8504,8521,8526,8493	,8523,8558	.	1.0	-1.74	0.568	0.6	ID=COSV57264120;OCCURENCE=2(large_intestine),1(central_nervous_system),1(haematopoietic_and_lymphoid_tissue),10(stomach),177(soft_tissue),4(small_intestine)	.	
4	55152092	55152092	G	T	PDGFRA	exonic	nonsynonymous SNV	ENSG00000134853;ENSG00000145216	rs121913265	ENSG00000134853:ENST00000257290:exon18:c.G2524T:p.D842Y,ENSG00000145216:ENST00000507166:exon19:c.G1804T:p.D602Y	PDGFRA:NM_006206:exon18:c.G2524T:p.D842Y	clinvar: Likely_pathogenic 	 CancerVar: 10#Tier_II_potential EVS=[1, 1, 0, 1, 0, 0, 1, 1, 2, 1, 1, 1] 	.	.	.	.	7.212	34	0.011	6.04	1.000	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	PDGFRA:uc003han.4:exon18:c.G2524T:p.D842Y,PDGFRA:uc003haa.3:exon19:c.G1804T:p.D602Y	0.289	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	173490	606764;607685;	3260;44890;	3260|-|Unknown|-|Adult|607685 ~44890|GIST<br>Gastrointestinal stromal sarcoma|1-5 / 10 000|Not applicable<br>or&nbsp;Autosomal dominant|Childhood<br>Adolescent<br>Adult|606764 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04020 Calcium signaling pathway~ko04072 Phospholipase D signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04510 Focal adhesion~ko04540 Gap junction~ko04630 JAK-STAT signaling pathway~ko04810 Regulation of actin cytoskeleton~ko05163 Human cytomegalovirus infection~ko05200 Pathways in cancer~ko05206 MicroRNAs in cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~	,8485,8486,8557,8529,8487,8488,8530,8528,8564	,8558	.	1.0	-1.76	0.625	0.95	ID=COSV57269122;OCCURENCE=2(central_nervous_system),3(soft_tissue)	MU81977161	
